Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Ampio Pharmaceuticals Inc. Stories

2012-01-17 14:09:00

GREENWOOD VILLAGE, Colo., Jan. 17, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), will hold a webcast on Thursday, January 26, 2012, at 4:15 p.m. EST. Management will outline the Company's 2012 milestones and will provide a detailed review for each of its three lead products. Dial-in Information United States:...

2012-01-17 06:00:00

GREENWOOD VILLAGE, Colo., Jan. 17, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane(TM) (Ampio's premature ejaculation (PE) drug) with any erectile dysfunction (ED) drug of the PDE5...

2012-01-09 08:24:00

In the news release, Executive Changes at Ampio, issued 09-Jan-2012 by Ampio Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the incorrect version of the release was issued inadvertently. The complete, corrected release follows: Executive Changes at Ampio GREENWOOD VILLAGE, Colo., Jan. 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved...

2012-01-09 06:00:00

GREENWOOD VILLAGE, Colo., Jan. 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced that CEO Don Wingerter would be granted a compassionate leave from all his duties at the company in order to attend to serious illnesses afflicting his closest family members. The term of leave is currently unknowable and should be considered...

2012-01-05 07:00:00

GREENWOOD VILLAGE, Colo., Jan. 5, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it will hold a Web Cast on Thursday, January 26, 2012 at 4:15 EST. The purpose of the call will be to update our shareholders on the company's progress and a press release on January 16th will announce how the...

2012-01-03 06:00:00

GREENWOOD VILLAGE, Colo., Jan. 3, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it is has completed the expanded patient enrollment phase of its Ampion(TM) In Knee (AIK) trials in Australia. Forty-two (42) patients were added to the original sixty (60) patient study. Dr. Vaughan Clift, Chief Regulatory...

2011-12-22 10:49:00

GREENWOOD VILLAGE, Colo., Dec. 22, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced notification of the granting of a Canadian patent with broad claims directed to: "METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". The protected compositions contain either DA-DKP, a cyclic dipeptide...

2011-12-21 09:35:00

GREENWOOD VILLAGE, Colo., Dec. 21, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE)("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced today that it has entered into definitive agreements with accredited investors to sell an aggregate approximately 2,220,255 of shares of its common stock, par value $0.0001 per share (the "Shares"), at a price per share of $4.25 in a...

2011-12-16 06:30:00

GREENWOOD VILLAGE, Colo., Dec. 16, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities, issued a statement in response to recent publications about the Company by anonymous short sellers. The Company believes increased volatility and volume in its common stock is a result of factually inaccurate and materially misleading information being...

2011-12-07 07:00:00

GREENWOOD VILLAGE, Colo., Dec. 7, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion(TM). The patent also includes...